Aurobindo Pharma announced that its newly-acquired US subsidiary Lannett has launched 100/50 mcg and 250/50 mcg strengths of a generic version of Advair Diskus fluticasone propionate / salmeterol xinafoate DPI in the US. Aurobindo notes that the inhaler “marks the first product from our inhalation pipeline to be commercialized in the US, reflecting our continued focus on expanding our portfolio of complex and differentiated inhalation products.”
Lannett acquired the US rights to Respirent’s generic equivalent of Advair Diskus in 2019. In early 2021, Respirent submitted its ANDA for the DPI in 100/50 mcg, 250/50 mcg, and 500/50 mcg strengths, and Lannett announced a few months later that the FDA had set a GDUFA goal date in January 2022 for review of the ANDA. According to the FDA web site, Respirent’s ANDA was approved on January 12, 2026.
Read the Aurobindo Pharma press release
